Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.160
+0.050 (4.50%)
At close: Feb 4, 2025, 4:00 PM
1.230
+0.070 (6.03%)
After-hours: Feb 4, 2025, 6:50 PM EST
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 5.38, with a low estimate of 1.50 and a high estimate of 7.00. The average target predicts an increase of 363.79% from the current stock price of 1.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coherus BioSciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +503.45% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +417.24% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +503.45% | Dec 4, 2024 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +244.83% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +934.48% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
263.60M
from 257.24M
Increased by 2.47%
Revenue Next Year
238.15M
from 263.60M
Decreased by -9.65%
EPS This Year
-0.88
from -2.53
EPS Next Year
-0.45
from -0.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 288.8M | 348.6M | 431.6M | |||
| Avg | 263.6M | 238.2M | 293.9M | |||
| Low | 238.7M | 42.6M | 92.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 12.2% | 32.2% | 81.2% | |||
| Avg | 2.5% | -9.7% | 23.4% | |||
| Low | -7.2% | -83.8% | -61.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.32 | 0.22 | 0.34 | |||
| Avg | -0.88 | -0.45 | -0.32 | |||
| Low | -1.96 | -1.68 | -1.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.